Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, CEO, appointed to Board Chair... Read More

PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de... Read More

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical... Read More

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans... Read More

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell... Read More

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025... Read More

Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg Trial to evaluate and enhance clinical experience with CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis PHILADELPHIA, Jan. 21, 2025 (GLOBE... Read More

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: Autoimmune... Read More

Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the... Read More

Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells, allowing for control of tumors in vivo without the need for exogenous or engineered cytokines Posters include demonstration of advances in gene... Read More

PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim’s Inaugural... Read More

Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer Chad Cowan, Ph.D., cell therapy pioneer, founder, and former CEO of Clade Therapeutics, appointed as Chief Scientific Officer Hy Levitsky, M.D., President of Research and Development, to transition to an advisor to Century PHILADELPHIA, Sept. 26, 2024 (GLOBE NEWSWIRE)... Read More

Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory Completed dose escalation for ELiPSE-1... Read More

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream Enrollment continues in dose escalation phase of ELiPSE-1 at... Read More

In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK mediated rejection in allogeneic cell therapies PHILADELPHIA, May 10, 2024 (GLOBE NEWSWIRE) -- Century... Read More

Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across... Read More

PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy... Read More

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century’s position as a leader in... Read More

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company’s... Read More

PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2 nd Annual Cell Therapy Virtual Conference on Tuesday, March 26... Read More

Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to... Read More

PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for... Read More

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday,... Read More

Data presented at 65 th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon... Read More

Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication Company plans to initiate the Phase 1 clinical trial in the first half of 2024; initial data expected by year-end 2024 CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR,... Read More

PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a... Read More

PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 10:00 AM ET. A replay of the event will... Read More

Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell lymphomas to be presented at the American Society of Hematology (ASH) Annual Meeting Announced expanded license agreements with FUJIFILM Cellular Dynamics (FCDI) for the development and commercialization of... Read More

Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of... Read More

PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, and FUJIFILM Cellular Dynamics , Inc., a leading global developer and manufacturer of human iPSCs and iPSC-derived cells, today announce a new worldwide license agreement and... Read More

CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support, and a safety switch Preliminary clinical data from a case study featured in ASH abstract shows complete response maintained in Dose Cohort 1 patient following completion of four 28-day cycles of CNTY-101 in Phase 1 ELiPSE-1 trial, the two most recent of which... Read More

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at... Read More

Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end Ended second quarter 2023 with cash, cash equivalents, and investments of $301.0 million; Cash runway expected into 2026 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage... Read More

Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end Ended first quarter 2023 with cash, cash equivalents, and investments of $334.8 million; Cash runway expected into 2026 PHILADELPHIA, May... Read More

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan’s 7 th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual... Read More

Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer Michael C. Diem, M.D., promoted to Chief Financial Officer Hy Levitsky, M.D., rejoins as President of Research and Development PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative... Read More

Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in... Read More

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting on Monday,... Read More

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences: H.C. Wainwright Cell Therapy Virtual Conference. The fireside chat will take place at 10:30... Read More

CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch ELiPSE-1 trial to test multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits designed to resist 3 major pathways of rejection PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. , (NASDAQ: IPSC), an... Read More

PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences in February: The Guggenheim Healthcare Talks Oncology Day. The fireside chat will take place at 3:55 PM ET on... Read More

Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma Employee headcount reduced by approximately 25 percent, extending cash runway into 2026 Phase 1 study of CNTY-101, Company's lead candidate targeting CD19, in relapsed/refractory B-cell lymphoma remains on track; No impact to partnered programs with Bristol Myers... Read More

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT. A live webcast of the event will be... Read More